• In early August 2026, CVS Health reported second-quarter sales of US$35,117 million and net income of US$2,979 million, while raising full-year GAAP diluted EPS guidance to US$6.84–US$7.04 and projecting at least US$414.00 billion in revenue and up to US$9.07 billion in net income attributable to CVS Health.
• At the same time, CVS Health overhauled its weight management offering around GLP-1 therapies, cutting MinuteClinic digital visit prices to US$29 and partnering with Eli Lilly to integrate transparent GLP-1 pricing and access through the CVS Health app across roughly 9,000 pharmacies.
• We’ll now examine how this combination of stronger earnings guidance and an expanded GLP-1 weight management platform affects CVS Health’s investment narrative.

Uncover the next big thing with 18 elite penny stocks that balance risk and reward.

CVS Health Investment Narrative Recap

To own CVS Health, you need to believe its integrated model of insurance, pharmacy and care delivery can turn scale into consistent, profitable growth despite reimbursement and medical cost pressures. The raised 2026 earnings guidance reinforces near term confidence in execution, while the biggest current risk remains margin and medical cost pressure in Health Care Delivery and Medicare Advantage. The latest results and outlook do not remove that risk, but they do suggest it is not worsening right now.

The revamped GLP 1 weight management program and Eli Lilly collaboration matter because they sit at the intersection of CVS’s digital investments and its pharmacy and care delivery footprint. If GLP 1 therapies remain a meaningful category, CVS’s 9,000 pharmacies, $29 MinuteClinic visits and app based pricing tools could support one of the key long term catalysts around deeper engagement and cross sell across its ecosystem.

But investors should also weigh how continuing reimbursement pressure at retail and in the PBM business could...

CVS Health's narrative projects $453.4 billion revenue and $10.7 billion earnings by 2029. This requires 3.8% yearly revenue growth and a $7.8 billion earnings increase from $2.9 billion today.

Uncover how CVS Health's forecasts yield a $114.88 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently see CVS Health’s fair value between US$104 and US$281 per share, reflecting very different expectations. When you set those views against the recent earnings guidance increase and GLP 1 expansion, it underlines how differently investors can weigh upside potential against reimbursement and medical cost risks, so it is worth comparing several viewpoints before forming your own.

Explore 4 other fair value estimates on CVS Health - why the stock might be worth just $104.01!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CVS Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free CVS Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CVS Health's overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.